Lilly to Acquire Calytrix Bio for Up to $1.5B

Eli Lilly has agreed to acquire Calytrix Bio, whose shareholders could receive up to $1.5 billion in cash, including an upfront payment and subsequent payments tied to clinical and regulatory milestones. The acquisition broadens Lilly's presence in myeloproliferative neoplasms and builds on its blood cancer capabilities, the companies said.

Calytrix, based in Wellesley Hills, Massachusetts, develops precision, disease-modifying therapies for myeloproliferative neoplasms, focusing initially on mutant calreticulin-driven essential thrombocythemia and myelofibrosis. Its lead preclinical asset is a biparatopic antibody designed to deliver pan-mutant activity by targeting both Type 1 and Type 2 mutant calreticulin.

Current drug therapies for essential thrombocythemia and myelofibrosis primarily manage symptoms and complications, leaving room for precision therapies directed at disease driver mutations. Mutant calreticulin provides a tumor-specific cell-surface target with potential to deplete the disease-driving mutant clone while sparing normal tissues and preserving healthy blood cell production, according to the release.

Calytrix President and CEO Brad Prosek said the company was founded on the belief that myeloproliferative neoplasm patients deserve therapies that do more than manage symptoms, and that Lilly will now advance the program through the clinic and explore its potential across the disease spectrum.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!

Sign up now!

  • <<
  • >>

Join the Discussion